Patents by Inventor Terry D. Connell

Terry D. Connell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adjuvant activities of mutants of LT-IIa and LT-IIb enterotoxin lacking binding to ganglioside
    Patent number: 7776338
    Abstract: The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: August 17, 2010
    Assignee: The Research Foundation of State University of New York
    Inventors: Terry D. Connell, Michael W. Russell, Hesham Nawar, Sergio Arce
  • ADJUVANT ACTIVITIES OF MUTANTS OF LT-IIa AND LT-IIb ENTEROTOXIN LACKING BINDING TO GANGLIOSIDE
    Publication number: 20090136535
    Abstract: The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.
    Type: Application
    Filed: November 5, 2008
    Publication date: May 28, 2009
    Inventors: Terry D. Connell, Michael W. Russell, Hesham Nawar, Sergio Arce
  • Adjuvant activities of mutants of LT-IIa and LT-IIb enterotoxin lacking binding to ganglioside
    Patent number: 7455843
    Abstract: The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: November 25, 2008
    Assignee: Research Foundation of State University of New York, The
    Inventors: Terry D. Connell, Michael W. Russell, Hesham Nawar, Sergio Arce
  • Chimeric antigen-enterotoxin mucosal immunogens
    Patent number: 6846488
    Abstract: The present invention provides methods of inducing immune responses by recombinant antigen-enterotoxin chimeric mucosal immunogens that contain the A2/B subunits of cholera toxin or heat-labile type II toxins. These chimeric immunogens differentially enhance antibody secretion, cytokine production, as well as B7-dependent co-stimulation of T cells and CD40L expression on CD4+ T cells.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: January 25, 2005
    Assignee: The UAB Research Foundation
    Inventors: Michael W. Russell, Terry D. Connell
  • Chimeric antigen-enterotoxin mucosal immunogens
    Publication number: 20020004238
    Abstract: The present invention provides methods of inducing immune responses by recombinant antigen-enterotoxin chimeric mucosal immunogens that contain the A2/B subunits of cholera toxin or heat-labile type II toxins. These chimeric immunogens differentially enhance antibody secretion, cytokine production, as well as B7-dependent co-stimulation of T cells and CD40L expression on CD4+ T cells.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 10, 2002
    Inventors: Michael W. Russell, Terry D. Connell